Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C

被引：0

作者：

Wu, J. ^{[1
]}

Zhou, C. ^{[1
]}

Yan, J. ^{[2
]}

Han, Z. ^{[3
]}

Wang, C. ^{[2
,5
]}

Qin, Z. ^{[4
]}

Jiang, J. ^{[1
]}

Wang, C. ^{[2
,5
]}

Tang, X. ^{[6
]}

Zhu, L. ^{[7
]}

Chen, J. ^{[8
]}

Mao, Y. ^{[9
]}

Wei, X. ^{[10
]}

Shangguan, C. ^{[1
]}

Zhang, J. ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China

[2] Jiading Cent Hosp, Dept Oncol, Shanghai, Peoples R China

[3] Xuzhou Med Univ, Affiliated Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China

[4] Zhejiang Prov Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China

[5] 3 Peoples Hosp Yancheng, Dept Oncol, Yancheng, Peoples R China

[6] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China

[7] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China

[8] Ningbo Univ, Affiliated Peoples Hosp, Dept Oncol, Ningbo, Peoples R China

[9] Jiangnan Univ, Wuxi Peoples Hosp 4, Dept Oncol, Wuxi, Jiangsu, Peoples R China

[10] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.285

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

150P

引用

页码：S1533 / S1533

页数：1

共 50 条

[1] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C
Wu, Junwei
Zhou, Chenfei
Yan, Jun
Han, Zhengxiang
Wang, Chun
Qin, Zhiquan
Jiang, Jinling
Wang, Chunbing
Tang, Xinyu
Zhu, Lingjun
Chen, Jun
Mao, Yong
Zhu, Liangjun
Wei, Xiaowei
Shangguan, Chengfang
Zhang, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Wu, Junwei
Zhou, Chenfei
Yan, Jun
Han, Zhengxiang
Wang, Chun
Qin, Zhiquan
Jiang, Jinling
Wang, Chunbin
Tang, Xinyu
Zhu, Lingjun
Chen, Jun
Mao, Yong
Wei, Xiaowei
Shangguan, Chengfang
Zhang, Jun
CANCER RESEARCH, 2024, 84 (07)
[3] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Wu, J.
Zhu, L.
Zhou, C.
Shi, M.
Chen, J.
Zhao, L.
Han, Z.
Wang, C.
Jiang, J.
Yan, J.
Wei, X.
Mao, Y.
Yang, X.
Qin, Z.
Tang, X.
Zhang, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1510 - S1511
[4] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
Wu, Junwei
Zhou, Chenfei
Yan, Jun
Han, Zhengxiang
Wang, Chun
Qin, Zhiquan
Jiang, Jinling
Wang, Chunbing
Tang, Xinyu
Zhu, Lingjun
Chen, Jun
Mao, Yong
Wei, Xiaowei
Shangguan, Chengfang
Zhang, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 653 - 653
[5] Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001)
Zhou, Chenfei
Wu, Junwei
Yan, Jun
Wang, Chun
Mao, Yong
Tang, Xinyu
Zhu, Lingjun
Chen, Jun
Wang, Chunbing
Qin, Zhiquan
Han, Zhengxiang
Shangguan, Chengfang
Zhang, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multicenter phase II trial (ALTER-G-001)
Wu, J.
Zhang, J.
Zhou, C.
Yan, J.
Zhu, L.
Jiang, J.
Wang, C.
Chen, J.
Han, Z.
Wang, C.
Yong, M.
Tang, X.
Qin, Z.
Wei, X.
Shangguan, C.
ANNALS OF ONCOLOGY, 2023, 34 : S902 - S902
[7] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
Zhou, C.
Zhang, J.
Wu, J.
Jiang, J.
Zhu, L.
Yan, J.
Wang, C.
Mao, Y.
Tang, X.
Chen, J.
Wang, C.
Qin, Z.
Han, Z.
Wei, X.
Shangguan, C.
ANNALS OF ONCOLOGY, 2023, 34 : S50 - S51
[8] Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001)
Liu, Jing
Wu, Junwei
Zhu, Liangjun
Yan, Jun
Mao, Yong
Tang, Xinyu
Zhu, Lingjun
Jiang, Hong
Wei, Xiaowei
Shangguan, Chengfang
Xi, Wenqi
Shi, Yan
Shi, Min
Zhou, Chenfei
Yang, Hui
Zhang, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[9] Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
Jin, Y.
Han, Y.
Zhang, L.
Jin, Y.
Sun, H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S720 - S721
[10] Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
Wu, Jun-Wei
Zhou, Chen-Fei
Han, Zheng-Xiang
Zhang, Huan
Yan, Jun
Chen, Jun
Wang, Chun-Bin
Qin, Zhi-Quan
Mao, Yong
Tang, Xin-Yu
Zhu, Liang-Jun
Wei, Xiao-Wei
Cui, Dong-Hai
Yang, Xiu-Li
Shi, Min
Zhao, Li-Qin
Jiang, Jin-Ling
Zhu, Wei-You
Wang, Hong-Mei
Wang, Chun
Zhu, Ling-Jun
Zhang, Jun
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)

← 1 2 3 4 5 →